Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03095456 · ClinicalTrials.gov registry record · Phase 3
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
A Phase 3 study, sponsored by Mylan.
- Completed
- Registry status
- Phase 3
- Development phase
- 207
- Enrollment target
NCT03095456 is a Phase 3 study that has completed, run by Mylan. The registered enrollment target is 207 participants.
The verdict
NCT03095456, a Phase 3 study, has completed, sponsored by Mylan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 207 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak Inspiratory Flow Rate.
Interventions
- DRUG Revefenacin
- COMBINATION_PRODUCT Spiriva Handihaler®
- DRUG Placebo for Revefenacin
- DRUG Placebo for Spiriva Handihaler®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2017-03-27 |
| Est. Completion | 2017-11-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03095456
The ClinicalTrials.gov registry entry for NCT03095456 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Revefenacin is the first listed.
NCT03095456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03095456 about?
NCT03095456 is a clinical study titled "Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD". This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak Inspiratory Flow Rate.
What is the current status of trial NCT03095456?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 207 participants. The study started on 2017-03-27. Estimated completion is 2017-11-25.
What interventions are being tested in trial NCT03095456?
The interventions under investigation include: Revefenacin (DRUG), Spiriva Handihaler® (COMBINATION_PRODUCT), Placebo for Revefenacin (DRUG), Placebo for Spiriva Handihaler® (DRUG).
Who is sponsoring clinical trial NCT03095456?
This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.